“ First, he underlined that this is preliminary data, based on about half the patients in the trial, and it "has not undergone the robust analysis that will be conducted by the statisticians and the scientists at the NIH in the coming weeks."
And while the preliminary data showed no serious side effects of remdesivir, "we still don't have all the safety data reported from the NIH, and that will be critically important to understanding how we use this medicine in the future," he said.
Mehta also noted that remdesivir isn't a cure-all.”
I am hoping that when Brilacidin becomes known as an excellent complementary drug for vaccines and proves its broad spectrum of uses that this will down the road propel IPIX's other drug, Kevetrin, into a broad, broad swath of trials as a an adjunct to many other cancer treatment drugs.
Many BPs will be shaking their heads and wondering how they ever let IPIX get away with two drugs possessing such explosive potential in so many high revenue streams of medicine.
Next week sometime starts the final step to allowing Brilacidin to be put to work on human patients for CV - hope it is for both a treatment and as a vaccine adjunct.
Correct NIH changed it's focus from Home Run to limited therapy. We know Remdesivir has just 1 of the 3 properties that Brilacidin has.
Tamiflu doesn't knock out the flu it makes it a little easier to recover from. Not a home run.
I think the Good Dr. may have jumped ahead with Remdesivir because it allows people to go home sooner 11 vs 15 days. I am very confident that when Brilacidin crosses the Bridge from Lab to Hospitals Trials we will be getting the ultimate recognition as the Home Run or solid Triple.
Fox Business has given it some airtime (wasn't much just a mention of the list but so it begins) only a matter of time before more in-depth coverage comes out in MSM.
Market Data 
Markets 
AI
